MDS

This study tests whether giving two drugs (decitabine and filgrastim) after a stem cell transplant can safely prevent leukemia or related blood cancers from coming back in children and young adults. About 37 participants with acute myeloid leukemia, myelodysplastic syndromes, or …

This study tests whether adding a precise, targeted form of radiation to the usual chemotherapy before a stem cell transplant can kill more cancer cells in the bone marrow and lower the chance of the disease coming back. It involves 27 adults aged 18-75 with acute leukemia or mye…

This study tests a stem cell transplant approach for people with blood cancers like AML and MDS. It uses milder chemotherapy (treosulfan and fludarabine) followed by a donor stem cell infusion, plus drugs to prevent graft-versus-host disease. The goal is to improve survival at 10…

This early-stage study tests an oral combination of tetrahydrouridine and decitabine in 20 adults with myelodysplastic syndromes (MDS) that relapsed or didn't respond to prior therapy. Participants take the drug once a week for 24 weeks and visit the clinic monthly. The main goal…

This study is for people with a low-risk form of myelodysplastic syndrome (MDS) who do not have ring sideroblasts and whose anemia has not improved with standard treatment. The trial tests whether adding a drug called luspatercept to another drug (ESA) works better than luspaterc…

This study tests whether a stem cell transplant from a healthy donor can treat GATA2 deficiency, a genetic condition that weakens the immune system and raises the risk of leukemia. Participants aged 6 to 70 receive chemotherapy or radiation before the transplant to prepare their …

This early-stage study tests a pre-made immune cell therapy (MT-401-OTS) for people aged 65+ with relapsed acute myeloid leukemia or high-risk myelodysplastic syndromes. The therapy uses donor T-cells designed to attack multiple cancer-related targets. The main goals are to check…

This early-phase study tests a new drug called CG009301 in adults with blood cancers (like leukemia or MDS) that returned or didn't respond to standard treatments. The main goals are to find a safe dose and check for side effects. About 45 participants will receive the drug until…

This study tests a new treatment called BSB-1001 for people with certain blood cancers (AML, ALL, or MDS) who have had a stem cell transplant. The therapy uses specially modified immune cells to target and kill cancer cells while trying to avoid harming healthy tissue. The main g…

This study tests a new treatment called CD70-CAR T cells for children and young adults up to age 21 with blood cancers like leukemia, lymphoma, or MDS that have come back or not responded to standard therapy. The treatment uses the patient's own immune cells, modified in a lab to…

This early-phase trial tests an experimental drug called eganelisib, given alone or with standard chemotherapy (cytarabine), in adults whose acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) has returned or not responded to prior treatment. The main goals …

This study tests whether a cord blood transplant can help children and young adults (up to age 21) with life-threatening blood cancers or non-cancerous blood disorders who do not have a matched family donor. The main goal is to see how many patients are alive without treatment-re…

This study aims to develop a new blood test to diagnose a bone marrow disorder called MDS, potentially replacing the need for a painful bone marrow biopsy. Researchers will collect blood samples from 1500 adults with low blood cell counts to see if the test can accurately detect …

This study looks at whether using a quality-of-life questionnaire to guide blood transfusions can reduce the number of transfusions for adults with advanced MDS or AML who are receiving palliative care. Participants will be randomly assigned to either the standard hemoglobin-base…

This research study aims to discover new genes that may cause cancer to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had childhood cancers. Participants will not receive direct treatment o…

This study is a large registry that will follow up to 2,300 people in China with various blood diseases, such as leukemia, multiple myeloma, and hemophilia. Researchers will collect information from medical records to understand how common these diseases are, what treatments peop…

This study follows about 1,000 people who previously received an experimental T-cell therapy (TSC-100 or TSC-101) for blood cancers like leukemia. Researchers will track participants for up to 15 years to see if any long-term side effects occur and how well they survive. The goal…

This study is a registry that collects information from 1,000 patients with blood diseases who receive stem cell transplants at a hospital on the Qinghai-Tibet Plateau. Researchers will track their health, treatments, and costs over time to learn how high altitude affects recover…